Skip to main content

Table 1 Macaque history and regimen of post exposure prophylaxis.

From: Post-exposure prophylaxis for SIV revisited: Animal model for HIV prevention

Group

Macaque

Treatment regimens

  

Uninterrupted PEP1

Outcome after 4–5 years.2

Second PEP regimen3

A

98021

Naïve

V-Ab-

Untreated

 

98034

Naïve

V-Ab-

Untreated

 

98035

Naïve

V-Ab-

Untreated

B

93192

24 h pi 28 d

V-Ab- (5)

10 wk, 6 ti

 

93208

24 h pi 28 d

V-Ab- (5)

10 wk, 6 ti

 

95025

24 h pi 28 d

V-Ab- (4)

10 wk, 6 ti

 

95044

24 h pi 28 d

V-Ab- (4)

10 wk, 6 ti

C

93194

-48 h pi 28 d

V-Ab-(5)

5 wk, 1 ti

 

95054

24 h pi 28 d

V-Ab- (4)

5 wk, 1 ti

 

93217

24 h pi 28 d

V-Ab- (5)

5 wk, 1 ti

 

93193

4 h pi 28 d

V-Ab- (5)

5 wk, 1 ti

D

M94312

24 h pi 28 d

V-Ab± (4)

5 wk, 1 ti

 

M95033

72 h pi 28 d

V-Ab± (4)

5 wk, 1 ti

 

95053

24 h pi 10 d

V-Ab± (4)

5 wk, 1 ti

 

93040

-48 h pi, 28 d +SIV challenge

V-Ab+ (5)

5 wk, 1 ti

 

93043

-48 h pi, 28 d +SIV challenge

V-Ab+ (5)

10 wk, 6 ti

E

95020

24 h pi 10 d

V-Ab± (4)

NONE

  1. All macaques in this study were cynomolgus macaques (Macaca fasicularis).
  2. 1PEP, post-exposure chemoprophylaxis; uninterrupted PEP (1st PEP) was performed using SIVmne infection and PMPA or PMEA as described in studies already published [15-17] 4–5 years prior to the present study (2nd PEP). The uninterrupted PEP regimen such as 24 h pi 28 d indicates 24 hours post inoculation and 28 days of treatment.
  3. 2V-Ab- indicates virus-negative and antibody-negative; V-Ab± indicates virus-negative and weakly seropositive, V-Ab+ indicates virus-negative and strongly seropositive. The numbers in brackets refers to years after uninterrupted PEP for follow-up of each macaque. Macaques 93040 and 93043 had been challenged with SIVsmmpBj14 at 12 months after uninterrupted PEP as described previously [17] prior to being used in the present study.
  4. 3For second PEP regimen, all previously SIV-exposed and PMPA-treated macaques were divided into groups (B – E) based in the pre-existing SIV-antibody response. Group A were three naïve macaques that served as infection controls for SIVmne virus stock. Macaques in group B and one macaque (93043) in group D were given a 10-week (10 wk) PMPA treatment that included weekly treatment interruption(ti) plus SIVmne challenge for the first six weeks of treatment (i.e. 10 wk, 6 ti). Macaques in groups C and D were given a 5-week (5 wk) PMPA treatment that included a single treatment interruption (ti) plus SIVmne challenge during the first week of treatment (i.e. 5 wk, 1 ti). Macaque 95020 in group E received uninterrupted PMPA PEP but not the second PMPA PEP and remained virus-negative and weakly seropositive throughout the follow-up studies.
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us